Global Briefing on Chronic Granulomatous Disease Market Report 2018: Symptoms, Treatment and Management

Chronic Granulomatous Disease Market is a rare inherited disorder which is passed on from parents to their children. People with this disease have weak immune systems which leave their body vulnerable to chronic inflammation and frequent bacterial and fungal infections.

The symptoms of this disease vary from person to person. Some common signs and symptoms may include frequent bacterial and fungal infections, swollen lymph nodes, persistent diarrhea, abscesses involving liver, lungs, spleen, bones, or skin.

Factors such as the growing prevalence of rare diseases, increasing expenditure on healthcare sector in the developed economies, and increasing research and development activities are anticipated to drive the growth of the market. However, expensive diagnostic tests and lack of awareness about the disease in the developing and underdeveloped economies may hinder the market growth over the forecast period. For instance, the cost of genetic testing ranges from USD 100 to USD 2,000.

Avail Sample Copy For this Report at: https://www.marketresearchfuture.com/sample_request/6447

Some of the prominent players in the global chronic granulomatous disease market are Pfizer, Inc., InterMune, Inc., Novartis AG, Lonza Group, GlaxoSmithKline Plc, Eli Lilly and Company, Janssen Pharmaceuticals, Merck KGaA, Osiris Therapeutics, Inc, JCR Pharmaceuticals Co., Ltd., Maxcyte Inc., and Horizon Pharma Plc.

The prominent players in the chronic granulomatous disease market are engaged in frequent new product launches and strategic collaborations to strengthen its market position. Currently, Actimmune (Interferon gamma-1b) manufactured by InterMune, Inc. is the approved by the US Food and Drug Administration (FDA) for treatment of chronic granulomatous disease.

Market Segmentation:

The market, on the basis of type, is segmented into X-linked chronic granulomatous disease and autosomal recessive chronic granulomatous disease.

The market, by diagnosis, has been segmented into neutrophil function tests, genetic testing, prenatal testing, and others.

The market, by treatment, has been segmented into infection management, interferon-gamma, stem cell transplantation, and others. The infection management segment has been further segmented into trimethoprim, sulfamethoxazole, itraconazole, and others.

On the basis of end user, the market has been segmented into hospitals, clinical laboratories, and others.

Geographically Chronic Granulomatous Disease Market Has Been Segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The chronic granulomatous disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

Brows Full Detailed Report at: https://www.marketresearchfuture.com/reports/chronic-granulomatous-disease-market-6447

The European chronic granulomatous disease market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The chronic granulomatous disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The chronic granulomatous disease market in the Middle East & Africa has been segmented into the Middle East and Africa.

On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector, and growing prevalence of CGD and growing government initiatives for the healthcare sector. As per to an article published in the National Center for Biotechnology Information (NCBI) in 2017, the incidence of CGD is 1 in 70,000 in the Israeli Arab population.

Enquire for Discount at: https://www.marketresearchfuture.com/check-discount/6447

Chronic granulomatous disease (CGD) is a rare inherited immune deficiency caused due to a random mutation in the DNA. People affected with this disease have weakened immune systems which do not function properly. CGD is of two types, namely, X-linked CGD and autosomal recessive type.

About Market Research Future:

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact:

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.